hesperidin has been researched along with empagliflozin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo-Youssef, AM; Hassan, MIA; Hemeida, RAM; Osman, AT; Sharkawi, SMZ | 2 |
2 other study(ies) available for hesperidin and empagliflozin
| Article | Year |
|---|---|
RETRACTED: Empagliflozin and neohesperidin mitigate methotrexate hepatotoxicity via Nrf2/PPARγ/HO-1 signalling initiation and suppression of NF-κB/Keap1/HSP70/caspase-3 axis in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Benzhydryl Compounds; Caspase 3; Chemical and Drug Induced Liver Injury; Glucosides; Heme Oxygenase (Decyclizing); Hesperidin; HSP72 Heat-Shock Proteins; Kelch-Like ECH-Associated Protein 1; Male; Methotrexate; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Protective Agents; Rats; Signal Transduction | 2021 |
Empagliflozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats.
Topics: Acetylcysteine; Animals; Benzhydryl Compounds; Glucosides; Hesperidin; Inflammation; Kidney; Kidney Diseases; Male; Methotrexate; Oxidative Stress; Protective Agents; Rats; Signal Transduction | 2021 |